These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37937429)

  • 21. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.
    Marsian J; Fox H; Bahar MW; Kotecha A; Fry EE; Stuart DI; Macadam AJ; Rowlands DJ; Lomonossoff GP
    Nat Commun; 2017 Aug; 8(1):245. PubMed ID: 28811473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines.
    Kouiavskaia D; Mirochnitchenko O; Troy S; Chumakov K
    Vaccine; 2023 Mar; 41(13):2147-2154. PubMed ID: 36828716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.
    Dawson ED; Taylor AW; Johnson JE; Hu T; McCormick C; Thomas KN; Gao RY; Wahid R; Mahmood K; Rowlen KL
    J Immunol Methods; 2022 May; 504():113259. PubMed ID: 35314144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
    Shimizu H
    Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
    Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
    J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.
    Swartz TA; Handsher R; Manor Y; Stoeckel P; Barkay A; Mendelson E; Leventhal A
    Vaccine; 1998 Dec; 16(20):2090-5. PubMed ID: 9796069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
    Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
    Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
    J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
    Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
    Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
    J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus.
    Liu S; Song D; Bai H; Lu W; Dai X; Hao C; Zhang Z; Guo H; Zhang Y; Li X
    J Med Virol; 2017 Dec; 89(12):2075-2083. PubMed ID: 28786502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.
    Foiadelli T; Savasta S; Battistone A; Kota M; Passera C; Fiore S; Bino S; Amato C; Lozza A; Marseglia GL; Fiore L
    BMC Infect Dis; 2016 Jun; 16():277. PubMed ID: 27287521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.
    Yeh MT; Smith M; Carlyle S; Konopka-Anstadt JL; Burns CC; Konz J; Andino R; Macadam A
    Nature; 2023 Jul; 619(7968):135-142. PubMed ID: 37316671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.
    Shaghaghi M; Soleyman-Jahi S; Abolhassani H; Yazdani R; Azizi G; Rezaei N; Barbouche MR; McKinlay MA; Aghamohammadi A
    Vaccine; 2018 Mar; 36(13):1711-1719. PubMed ID: 29478755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.
    Kumar P; Bird C; Holland D; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Dec; 18(7):2154100. PubMed ID: 36576132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virology. 'Biased' viruses suggest new vaccine strategy for polio and other diseases.
    Enserink M
    Science; 2008 Jun; 320(5884):1709. PubMed ID: 18583587
    [No Abstract]   [Full Text] [Related]  

  • 37. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
    Gupta D; Parthasarathy H; Sah V; Tandel D; Vedagiri D; Reddy S; Harshan KH
    Virus Res; 2021 Nov; 305():198555. PubMed ID: 34487766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
    De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
    Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
    Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
    J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.